In 2023, George Scangos, Ph.D. earned $1.80M in total compensation at Vir Biotechnology, Inc., including $325.00K salary and $1.46M in stock. Currently holds stock worth $16.81M. Led Vir Biotechnology, Inc. as CEO for 3 years.
Compensation History
Annual executive compensation data for George Scangos, Ph.D., including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$1.80M
Salary
$325.00K
Bonus
$0.00
Other
$13.20K
Salary
$325.00KBoard Justification
The compensation philosophy emphasizes alignment with company performance and retention of key executives during transitions.
Bonus
$0.00Board Justification
Not eligible for payouts under the 2023 annual incentive plan due to the timing of departure.
Other Compensation
$13.20KBoard Justification
Includes matching contributions made under the 401(k) plan.
Restricted Stock
Board Justification
55,000 shares of common stock vested in 2023 as part of his compensation package.
Performance Metrics
Not applicable as he was not eligible for performance-based compensation in 2023.
George Scangos, Ph.D.
Ex-CEO of Vir Biotechnology, Inc.
Education
Ph.D. in Biochemistry from the University of California, San Francisco.
Field of Expertise
Healthcare & Life Sciences - Biotechnology
Sector of Economy
Healthcare
Born
June 9, 1958 - 67 years ago
CEO of Vir Biotechnology, Inc. for
3 years 2 months (Jan 2020 - Apr 2023)
Previous Experience
Former CEO of several biopharmaceutical companies, including Aileron Therapeutics and BioMarin Pharmaceutical.
Other Vir Biotechnology, Inc. CEOs
Holdings
Track George Scangos, Ph.D.'s stock holdings and portfolio value over time.
Insider Trading
George Scangos, Ph.D.'s recent stock transactions, purchases, and sales filed with the SEC.
No insider trades found for this CEO.
Rivals
Compare George Scangos, Ph.D. with competitor CEOs and industry peers.